Publication date: 1 November 2026 Source: Drug and Alcohol Dependence, Volume 288 Author(s): Gerald Cochran, Marcela Smid, Daniel Lewis, Michelle Lofwall, Elizabeth E. Krans, Jennifer P. Wisdom, Davida M. Schiff, Jessica R. Gray, Constance Guille, Mitra Lewis, Viviana E. Horigian, Peter R. Martin, Frankie Kropp, T. John Winhusen
Extended-release injection vs sublingual buprenorphine for illicit opioid use in pregnant patients with depression and/or anxiety. // Drug and Alcohol Dependence. – URL: https://www.sciencedirect.com/science/article/pii/S037687162600339X?dgcid=rss_sd_all
Extended-release injection vs sublingual buprenorphine for illicit opioid use in pregnant patients with depression and/or anxiety. Drug and Alcohol Dependence. https://www.sciencedirect.com/science/article/pii/S037687162600339X?dgcid=rss_sd_all
“Extended-release injection vs sublingual buprenorphine for illicit opioid use in pregnant patients with depression and/or anxiety.” Drug and Alcohol Dependence.
@article{article43501,
title = {Extended-release injection vs sublingual buprenorphine for illicit opioid use in pregnant patients with depression and/or anxiety},
journal = {Drug and Alcohol Dependence},
url = {https://www.sciencedirect.com/science/article/pii/S037687162600339X?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...